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Background: Nuclear factor of kappa B inhibitor alpha (IBa) protein is implicated in regulating a variety of cellular
process from inflammation to tumorigenesis. The objective of this study was to investigate the susceptibility of
rs2233408 T/C genotype in the promoter region of IBa to gastric cancer and the association of this
polymorphism with clinicopathologic variables in gastric cancer patients.
Methods: A population-based case-control study was conducted between 1999 and 2006 in Guangdong Province,
China. A total of 564 gastric cancer patients and 566 healthy controls were enrolled in this study. rs2233408
genotypes in IBa were analyzed by TaqMan SNP genotyping assay.
Results: Both rs2233408 T homozygote (TT) and T heterozygotes (TC and TT) had significantly reduced gastric
cancer risk (TT: OR = 0.250, 95% CI = 0.069-0.909, P = 0.035; TC and TT: OR = 0.721, 95% CI = 0.530-0.981, P =
0.037), compared with rs2233408 C homozygote (CC). rs2233408 T heterozygotes were significantly associated with
reduced risk of intestinal-type gastric cancer with ORs of 0.648 (95% CI = 0.459-0.916, P = 0.014), but not with the
diffuse or mix type of gastric cancer. The association between rs2233408 T heterozygotes and gastric cancer
appeared more apparent in the older patients (age>40) (OR = 0.674, 95% CI = 0.484-0.939, P = 0.02). rs2233408 T
heterozygotes was associated with non-cardiac gastric cancer (OR = 0.594, 95% CI = 0.411-0.859, P = 0.006), but
not with cardiac gastric cancer. However, rs2233408 polymorphism was not associated with the prognosis of
gastric cancer patients.
Conclusions: IBa rs2233408 T heterozygotes were associated with reduced risk of gastric cancer, especially for
the development of certain subtypes of gastric cancer in Chinese population.
Background
Nuclear factor-B (NF-B) regulates many cellular func-
tions including cell proliferation, apoptosis, angiogenesis,
immune response, cell adhesion and differentiation [1].
NF-B pathway plays important roles in linking inflam-
mation to tumour development and progression in
humans and mice [1]. Under unstimulated condition,
NF-B is inhibited by inhibitor nuclear factor-kappa B
(IB). Many oncogenes and carcinogens cause phos-
phorylation of IB through the NF-B inhibitor kinase
(IKK) complex and proteasome-mediated degradation of
IB, leading to release of activated NF-B [2]. The acti-
vated NF-B system provides the cells with the produc-
tion of growth factors as well as resistance to apoptotic
and genotoxic insults, contributing to tumour growth
and angiogenesis [1].
The IBp r o t e i n si n c l u d eI Ba,I Bb,I Bg,I Bε,B -
cell CLL/lymphoma 3 (BCL3), p105 and p100 [2]. IBa
gene, the main inhibitor of the NF-B signaling, is
located on chromosome 14q13 with 6 exons spanning
approximately 3.5 kb. Polymorphisms in the promoter
and exon region in the IBa gene have been reported to
be associated with inflammatory diseases and cancers
[3-8]. rs696 AG genotype in the 3’-UTR of IBa was
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any medium, provided the original work is properly cited.associated with an increased risk of developing colorec-
tal cancer in Chinese elderly population [3]. IBa
rs3138054 A/G (+1678) and rs2233419 C/T (+2025)
polymorphism showed different frequency distributions
between patients with multiple myeloma and controls
[5]. Kim L et al reported that there was no significant
association of IBa polymorphisms with development of
hepatocellular carcinoma among chronic hepatitis B
patients [6]. IBa -826 polymorphism and -826T/-
550A/-519C haplotype were significantly associated
increased risk of rheumatoid arthritis [7]. The frequency
of haplotype GTC (-881G/-826T/-297C) was signifi-
cantly higher among patients with acute respiratory dis-
tress syndrome in Caucasians [8]. However, the
association of IBa promoter polymorphism with gastric
cancer is still unknown. We sequenced the 2 kb promo-
ter region of IBa on 32 gastric cancer tissues and 34
normal gastric tissues and found that rs2233408 poly-
morphism showed bigger difference of the distribution
between gastric cancer patients as compared with the
control subjects. Thus, we conducted a large-scale case-
control study on Chinese population to investigate the
association of rs2233408 polymorphism with gastric




A population-based case-control study was conducted
between 1999 and 2006 in Guangdong Province, China.
T h ec a s es e r i e si n c l u d e d1 0 1 0C h i n e s eg a s t r i cc a n c e r
patients, diagnosed in the First Affiliated Hospital of
Sun Yat-sen University, Guangzhou and the Oncology
Hospital, Guangzhou from January 1999 to December
2006. Diagnosis was confirmed histologically as gastric
cancer. The median duration of follow-up was 14
months (ranging from 0 to 98 months). Clinical data of
patients were collected from medical record and struc-
tured interview of patients using a questionnaire.
Because 187 of the patients were transferred to other
hospitals with their medical history records or unwilling
to complete the questionnaires, some clinical data of
patients was unable to be traced, leaving a total of 823
with sufficient clinical information available. Since the
DNA samples of gastric cancer were extracted from par-
affin-embedded tissues, 564 gastric cancer cases with
both good DNA quality and sufficient clinical data were
selected for genotyping. All patients diagnosed to have
gastric cancer received surgical resection of the tumor.
The control series included 1500 Cantonese healthy
subjects from the general population of Guangzhou in
southern China. Among them, 566 control subjects were
randomly selected, frequency matched to the case group
by age and gender. There are 373 males (66%) and 191
females (34%) in 564 gastric cancer cases whereas there
are 354 males (63%) and 212 females (37%) in 566 con-
trol subjects. In the literature, the percentage of
rs2233408 TC/TT genotype in Asian populations ranged
from 11% to 21% [6,7]. With the sample size in the pre-
sent study, we have a study power of 76-93% to detect
an OR of 1.5 or 0.7 at a significance level of 0.05.
Patients and control subjects gave informed consent for
participation in this study and the study protocol was
approved by the Clinical Research Ethics Committee of
the Sun Yat-sen University of Medical Sciences.
DNA extraction
Genomic DNA was extracted from paraffin-embedded tis-
sues of 1010 gastric cancer patients using QIAamp DNA
Mini Kit (Qiagen, Germany) and from 2 ml peripheral
blood of 1500 healthy controls using Gentra Puregene
Blood Kit (Gentra Systems, Inc., Minneapolis, MN) All
extracted DNA was resuspended in UltraPure RNAse/
DNAse-Free Distilled water (Invitrogen, Carlsbad, CA).
IBa genotyping
IBa genotyping was performed by TaqMan(R) allelic
discrimination using predesigned Custom TaqMan SNP
Genotyping Assays kit (Applied Biosystems). The pri-
mers and probes for rs2233408 genotyping are 5’-
GAAACACCGGCGCGG-3’,5 ’-TTTGCTTTCCCCA-
GACTTCTAAGG-3’,5 ’-CTGCAGCCTCCTAAC-3’
(VIC), 5’-TGCAGCCCCCTAAC-3’ (FAM). PCRs were
run in a 20 μl reaction solution containing 200 ng of
template DNA, 10 μl TaqMan Universal PCR Master
Mix No AmpErase UNG (2×) (Applied Biosystems) and
0.5 μl 40×SNP Genotyping Assay (Applied Biosystems).
PCR was performed at 95°C for 10 min and 40 cycles at
92°C for 15 sec and 60°C for 1 min. The samples were
amplified, read and analyzed in Applied Biosystems
7500 Real-Time PCR System (Applied Biosystems).
Statistics
Hardy-Weinberg equilibrium of alleles at IBa loci was
assessed by c
2 tests. The effects of the genotypes at
IBa loci on the risk of gastric cancer were represented
as odds ratios (OR) with 95% confidence interval (CI) by
logistic regression. OR estimates for Lauren types and
tumor location were adjusted for age and gender. OR
estimates in age groups were adjusted for gender. Rela-
tionships between IBa polymorphism and clinico-
pathologic characteristics of gastric cancer patients were
compared using contingency tables and Pearson’s c
2
test. Kaplan-Meier survival curves and the log-rank test
for trend were used to evaluate the relationship between
IBa polymorphisms and the prognosis from the date
of primary diagnosis to the end of follow-up. The pri-
mary outcome is the overall survival of gastric cancer
patients. The multivariate Cox regression analysis was
performed to assess the prognostic value of IBa poly-
morphisms with adjustment for age, gender, tumor size
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ratios (HR) and 95% CI for each factor in multivariate
analysis were calculated from the Cox regression model.
Differences were regarded significant at P < 0.05. All the
above statistical analyses were performed using SAS
software (SAS Institute, Inc., Cary, North Carolina).
Results
IBa polymorphism was associated with reduced risk of
gastric cancer
Before genotyping, we conducted Hardy-Weinberg equi-
librium analysis of rs2233408 polymorphism. We found
that the alleles of rs2233408 polymorphism were in
Hardy-Weinberg equilibrium with non-significant c
2
values (P = 0.25). Analysis of rs2233408 genotype poly-
morphism showed a significant difference between gas-
tric cancer patients and controls (Table 1). Gastric
cancer patients had significantly lower carriage rate of
rs2233408 TT genotype and T heterozygotes (TC and
TT) with reduced ORs of 0.250 (95% CI = 0.069-0.909,
P = 0.035) and of 0.721 (95% CI = 0.530-0.981, P =
0.037) than controls (Table 1), suggesting a dominative
effect of T allele. The allele frequency of rs2233408 T
was significantly reduced in gastric cancer patients com-
pared with that of the controls (OR = 0.696, 95% CI =
0.523-0.925, P = 0.013) (Table 1).
IBa polymorphism was associated with intestinal-type
gastric cancer
We evaluated the role of rs2233408 polymorphism in dif-
ferent subtypes of gastric cancer. Stratified by the Lauren
classification, rs2233408 overall T carriers (TC and TT)
were also significantly lower in patients of intestinal type
gastric cancer (OR = 0.648, 95% CI = 0.459-0.916, P =
0.014), as compared with rs2233408 CC genotype (Table
2). However, there was no significant association of
rs2233408 genotypes with mix type or diffuse type gastric
cancer probably due to the small number of diffuse/mix
type gastric cancer cases (Table 2).
Association between IBa rs2233408 polymorphism and
age-at-onset of gastric cancer
The roles of rs2233408 polymorphism in gastric cancer
in different age groups were evaluated. Since gastric
cancer in younger patients under the age of 40 showed
a different genetic background and pathogenic mechan-
ism of disease from conventional gastric cancers [9-12],
the subjects were divided into two age groups (age < =
40 and age >40). In the age group of >40, rs2233408
overall T carriers (TC and TT) remained to be signifi-
cantly associated with gastric cancer compared with
rs2233408 CC genotype (OR = 0.674, 95% CI = 0.484-
0.939, P = 0.020) (Table 3). However, the associations of
this polymorphism was not statistically significant in the
younger age group (age <40) (Table 3).
IBa polymorphism was associated with non-cardiac
gastric cancer
We evaluated whether the association between
rs2233408 polymorphism and gastric cancer was modi-
fied by the tumor location: cardiac or non-cardiac gas-
tric cancer. rs2233408 overall T carriers (TC and TT)
showed lower prevalence in non-cardiac gastric cancer
than in controls (OR = 0.594, 95% CI = 0.411-0.859, P =
0.006) (Table 4). However, no significant difference was
observed between cardiac gastric cancer patients and
controls.
Association of IBa polymorphism with H. pylori infection
To evaluate whether H. pylori prevalence was influenced
by IBa rs2233408 polymorphisms, the distributions of
H. pylori infection between rs2233408 genotypes were
examined (Table 5). There was no significant association
of rs2233408 genotypes with H. pylori infection.
IBa polymorphism was not associated with the survival
of gastric cancer patients
Kaplan-Meier survival curves showed that overall survi-
val of the gastric cancer patients were not significantly
Table 1 Adjusted Odds Ratios (ORs) and 95% Confidence
Intervals (CIs) for gastric cancer in relation to IBa
rs2233408 genotypes and alleles
Controls (%) Cases (%) OR* (95%CI) P-value
Genotype
CC 451 (79.7) 476 (84.4) 1
TC 104 (18.4) 85 (15.1) 0.771 (0.562-1.059) 0.108
TT 11 (1.9) 3 (0.5) 0.250 (0.069-0.909) 0.035
TC/TT 115 (20.3) 88 (15.6) 0.721 (0.530-0.981) 0.037
Allele
C 1006 (88.9) 1037 (91.9) 1
T 126 (11.1) 91 (8.1) 0.696 (0.523-0.925) 0.013
[NOTE] *Adjusted for age and gender.
Table 2 Adjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for gastric cancer, stratified by Lauren type, in
relation to IBa rs2233408 genotypes
Genotype Intestinal Diffuse Mix
Control Cases OR* (95% CI) P-value Cases OR* (95% CI) P-value Cases OR* (95%CI) P-value
CC 451 354 1 27 1 64 1







[NOTE] *Adjusted for age and gender. Among 564 patients, 35 patients have missing data on Lauren classification.
Wang et al. BMC Gastroenterology 2010, 10:15
http://www.biomedcentral.com/1471-230X/10/15
Page 3 of 6different among different rs2233408 genotypes (Figure
1). In the multivariate Cox regression analysis, tumor
size grade, lymph node status, and distant metastasis
were significantly associated with the survival of gastric
cancer patients (Table 6). However, rs2233408 geno-
types were not associated with the outcome in gastric
cancer patients (Table 6).
Discussion and Conclusions
In the present study, IBa rs2233408 T heterozygotes
and homozygote were significantly associated with
reduced risk of gastric cancer in southern Chinese
population. This result was consistent with the report
by Lin et al who demonstrated that rs2233408 T allele
w a sm o r ep r e v a l e n ti nh e a l t h yc o n t r o l st h a ni np a t i e n t s
with rheumatoid arthritis probably due to different tran-
scriptional activities of IBa and the consequent activity
of NF-B [7].
We further demonstrated that IBa rs2233408 poly-
morphism was associated with reduced risk of intestinal
type gastric cancer rather than the diffuse-type. It has
been known that the development of the intestinal-type
malignancy is a longer multistep process via gastric atro-
phy, intestinal metaplasia, dysplasia and ultimately intest-
inal-type carcinoma. However, diffuse-type gastric cancer
occurred without the intermediate steps. NF-Be x p r e s -
sion in gastric tissues increased with the progression of
precancerous gastric lesions including intestinal metapla-
sia, dysplasia to gastric carcinoma [13]. Thus, IBa/NF-
B pathway seemed more involved in the progression of
the intestinal-type carcinoma. In addition, bile acid
induced NF-B-dependent the intestine-specific tran-
scription factor caudal type homeobox 2 (Cdx-2) expres-
sion and Cdx-2 downstream target guanylyl cyclase C,
which promoted the malignant transition from
inflammation to metaplasia carcinoma [14]. Cdx-2 is
intestine-specific transcription factor mediating the
extracellular matrix-mediated intestinal cell differentia-
tion and is associated with intestinal-type gastric cancer
[15-19]. Thus one possible explanation for the associa-
tion of IBa polymorphism with intestinal-type gastric
cancer was that different production of NF-B inhibitor
IBa mediated by IBa polymorphism led to different
NF-B activation and downstream Cdx-2 expression,
promoting transition from inflammation, intestinal meta-
plasia to carcinoma.
On the other hand, since the number of diffuse/mix
type gastric cancer is small, we could not make an affir-
mative conclusion on association between rs2233408
polymorphism and diffuse/mix gastric cancer. Therefore
future studies are warranted to examine the association
of rs2233408 polymorphism with diffuse/mix gastric
cancer by collecting new samples from patients with dif-
fuse/mix type gastric cancer.
IBa rs2233408 polymorphism was also associated
with elderly gastric cancer patients, but was not asso-
ciated with early-onset gastric cancers. Early onset and
conventional gastric cancer appears to have a different
genetic background and different pathogenic disease
mechanism [12,20]. Milne AN et al found that early-
onset gastric cancers displayed a COX-2 low, trefoil fac-
tor-1-expressing phenotype, whereas COX-2 over-
Table 3 Adjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for gastric cancer in relation to IBa
rs2233408 genotypes, stratified by age groups
Age ≦ 40 Age >40
Genotype Controls Cases OR* (95% CI) P-value Controls Cases OR* (95% CI) P-value
CC 91 52 1 360 424 1
TC/TT 18 11 1.033 (0.449-2.377) 0.939 97 77 0.674 (0.484-0.939) 0.020
[NOTE] *Adjusted for gender.
Table 4 Adjusted Odds Ratios (ORs) and 95% Confidence Intervals (CIs) for gastric cancer, stratified by tumor location,
in relation to IBa rs2233408 genotypes
Genotype Cardiac Non-cardiac
Controls Cases OR* (95% CI) P-value Cases OR* (95% CI) P-value
CC 451 121 1 310 1
TC/TT 115 32 1.021 (0.649-1.607) 0.927 47 0.594 (0.411-0.859) 0.006
[NOTE] *Adjusted for age and gender. Among 564 patients, 54 patients have missing data on tumor location.
Table 5 The distribution of IBa rs2233408
polymorphisms in gastric cancer patients
Genotype H. pylori infection P-value
Negative (%) Positive (%)
CC 143 (88%) 90 (86%) 0.576
TC/TT 19 (12%) 15 (14%)
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ventional cancers [20]. We also found IL-1B-511 poly-
morphism was associated with gastric cancer in elderly
group rather than younger group of patients [21]. These
findings suggested that the transition from pre-cancer-
ous lesions to malignancy of multi-steps gastric carcino-
genesis was a lengthy process, in which pro-
inflammatory factors such as COX-2, IL-1B and IBa
may be involved.
IBa rs2233408 polymorphism was found to be asso-
ciated with non-cardiac cancer but not cardiac cancer.
Non-cardiac cancer rather than cardiac cancer were con-
sistent with the current view that the development of
malignancy is a long multistep process from chronic gastri-
tis induced by H. pylori infection, atrophic gastritis with
loss of acid secretion, dysplasia and finally to cancer [22].
Atrophy, H. pylori infection and hypochlorhydira were
associated with increased risk of non-cardiac gastric cancer
but protected against cardia and esophageal adenocarcino-
mas [23]. Proinflammatory cytokine gene polymorphisms
including interleukin-1b, interleukin-1 receptor antagonist,
interleukin-10 and tumor necrosis factor-A increased the
risk of non-cardiac gastric adenocarcinoma but not cardia
and esophageal adenocarcinomas [23]. These findings col-
lectively suggested that non-cardiac cancer is genetically
different with the cardiac cancer.
The association of IBa rs2233408 polymorphism
with gastric cancer patient outcome was also evaluated.
Patients with IBa rs2233408 T heterozygotes did not
show better prognosis than those with C homozygote as
determined by Kaplan-Meier analysis or by multivariate
Figure 1 Kaplan-Meier survival curves show that overall survival of gastric cancer patients is not associated with IBa rs2233408
genotypes. P value was calculated using a log-rank test.
Table 6 Cox multivariate regression analysis of potential
factors for overall survival in gastric cancer patients
Variable HR (95% CI) P-value
Age 1.01 (0.99-1.02) 0.44
Gender
Male 1
Female 0.99 (0.71-1.38) 0.96
Tumor staging
T1 1
T2 4.49 (0.56-36.25) 0.16
T3 7.44 (1.00-55.67) 0.05
T4 10.01 (1.31-76.70) 0.03
Lymph node
Negative 1
Positive 2.52 (1.52-4.20) 0.0004
Metastasis
No 1
Yes 2.94 (1.96-4.40) < .0001
Lauren Classification
Intestinal 1
Diffuse or Mix 0.92 (0.54-1.58) 0.76
Location
Cardiac 1
Non-Cardiac 0.91 (0.61-1.34) 0.62
Differentiation
Poor 1
Moderate or Well 1.24 (0.81-1.90) 0.31
rs2233408 genotype
CC 1
TC/TT 0.69 (0.42-1.12) 0.13
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polymorphism did not affect gastric cancer out come.
Other factors, including tumor size grades, lymph node
status and distant metastasis, were significantly corre-
lated with the survival of gastric cancer patients.
In conclusion, rs2233408 T heterozygotes had signifi-
cantly reduced gastric cancer risk, compared with
rs2233408 C homozygote genotype in southern Chinese.
In addition, there is heterogeneity in the risk of different
sub-types for gastric cancer susceptibility in IBa poly-
morphism. rs2233408 polymorphism was associated
with increased risk of intestinal-type, non cardiac and
elderly gastric cancers.
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